Dexamethasone preparation does not alter corticoid and androgen responses to adrenocorticotropin.

Rosenfield RL, Helke J, Lucky AW

The Journal of clinical endocrinology and metabolism1 Mar 1985Cited by 26 (Europe PMC)

PMID2982902DOI10.1210/jcem-60-3-585PepBankPUB-02982902

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cosyntropin.

01HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In participants undergoing cosyntropin tests, dexamethasone pretreatment did not alter absolute plasma steroid levels achieved after stimulation.
In plain wordsIn cosyntropin tests, absolute steroid levels were unchanged with dexamethasone pretreatment compared with no pretreatment.
Peptide
Cosyntropin
Outcome
No significant changeAbsolute plasma steroid response
Study
n: not reported in source
Comparator
Cosyntropin test without dexamethasone pretreatment
Outcome group
Adrenal Function · Endocrine and hormones
Source sentences
Summary
Dex did not alter the absolute plasma steroid levels achieved in response to ACTH.
2 context sentences(design, population, supporting numbers)
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290201
02HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In participants undergoing cosyntropin tests, dexamethasone pretreatment increased the 17 alpha-hydroxypregnenolone increment compared with no pretreatment.
In plain wordsIn cosyntropin tests, the 17 alpha-hydroxypregnenolone rise was greater with dexamethasone pretreatment than without it.
Peptide
Cosyntropin
Outcome
Increase17 alpha-hydroxypregnenolone increment
Study
n: not reported in source
Comparator
Cosyntropin test without dexamethasone pretreatment
Outcome group
Adrenal Function · Endocrine and hormones
Source sentences
Summary
However, since post-dex baseline concentrations of adrenal steroids were lower, the delta to ACTH was significantly greater for the major adrenal secretory products, 17 alpha-hydroxypregnenolone (3 beta, 17 alpha-dihydroxypregn-5-ene-20-one), dehydroepiandrosterone, and cortisol (F).
2 context sentences(design, population, supporting numbers)
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290202
03HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In participants undergoing cosyntropin tests, dexamethasone pretreatment increased the dehydroepiandrosterone increment compared with no pretreatment.
In plain wordsIn cosyntropin tests, the dehydroepiandrosterone rise was greater with dexamethasone pretreatment than without it.
Peptide
Cosyntropin
Outcome
IncreaseDehydroepiandrosterone increment
Study
n: not reported in source
Comparator
Cosyntropin test without dexamethasone pretreatment
Outcome group
Adrenal Function · Endocrine and hormones
Source sentences
Summary
However, since post-dex baseline concentrations of adrenal steroids were lower, the delta to ACTH was significantly greater for the major adrenal secretory products, 17 alpha-hydroxypregnenolone (3 beta, 17 alpha-dihydroxypregn-5-ene-20-one), dehydroepiandrosterone, and cortisol (F).
2 context sentences(design, population, supporting numbers)
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290203
04HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In paired cosyntropin tests, mean cortisol at 30 minutes was 26.0 ± 4.4 micrograms/dl without dexamethasone and 23.8 ± 5.5 after pretreatment.
In plain wordsIn cosyntropin tests, cortisol levels after stimulation were similar with and without dexamethasone pretreatment.
Peptide
Cosyntropin
Outcome
No significant changeCortisol concentration after stimulation
Study
n: not reported in source
Comparator
Cosyntropin test without dexamethasone pretreatment
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Cortisol
26 micrograms/dl
without dex
SD
4.4 micrograms/dl
without dex
Cortisol
23.8 micrograms/dl
after dex
SD
5.5 micrograms/dl
after dex
Source sentences
Summary
For example, for all paired tests, the mean plasma F values achieved 30 min post-ACTH were 26.0 +/- 4.4 (+/- SD) micrograms/dl without dex and 23.8 +/- 5.5 micrograms/dl after dex.
3 context sentences(design, population, supporting numbers)
Summary · context
Dex did not alter the absolute plasma steroid levels achieved in response to ACTH.
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290204
05HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In paired cosyntropin tests, dexamethasone increased the cortisol increment from 13.3 ± 4.8 to 19.4 ± 3.3 micrograms/dl (P < 0.001).
In plain wordsIn cosyntropin tests, cortisol rose more after dexamethasone pretreatment than without it.
Peptide
Cosyntropin
Outcome
IncreaseCortisol increment after stimulation
Study
n: not reported in source
Comparator
Cosyntropin test without dexamethasone pretreatment
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Cortisol increment
13.3 micrograms/dl
without dex
SD
4.8 micrograms/dl
without dex
Cortisol increment
19.4 micrograms/dl
after dex
SD
3.3 micrograms/dl
after dex
P
< 0.001
paired comparison
Source sentences
Summary
In contrast, the mean delta of plasma F 30 min post-ACTH was less without (13.3 +/- 4.8 micrograms/dl) than after (19.4 +/- 3.3 micrograms/dl) dex (P less than 0.001).
2 context sentences(design, population, supporting numbers)
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290205
06HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In follicular-phase women, dexamethasone-prepared cosyntropin tests showed skewed 21-hydroxylase efficiency without clear separation between 15% of the population and CAH heterozygotes.
In plain wordsIn follicular-phase women, prepared cosyntropin tests did not clearly separate CAH carriers from 15% of the population.
Peptide
Cosyntropin
Outcome
Not applicableApparent 21-hydroxylase efficiency distribution
Study
n: not reported in source
Comparator
Women heterozygous for CAH
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
Population without clear separation
15%
follicular phase
Source sentences
Summary
Apparent 21-hydroxylase efficiency, computed from dex-prepared tests, was found in follicular phase women to have a markedly skewed distribution without clear demarcation between 15% of the population and CAH heterozygotes.
2 context sentences(design, population, supporting numbers)
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290206
07HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In dexamethasone-pretreated women, the 17-hydroxyprogesterone level after cosyntropin was higher in the luteal phase than the follicular phase.
In plain wordsIn pretreated women, the hormone level after cosyntropin was higher in the luteal phase than the follicular phase.
Peptide
Cosyntropin
Outcome
Increase17-hydroxyprogesterone concentration after stimulation
Study
n: not reported in source
Comparator
Follicular phase
Outcome group
Adrenal Function · Endocrine and hormones
Source sentences
Summary
In the luteal phase, although the plasma 17-hydroxyprogesterone level at 30 min was higher, a response to ACTH was not consistently found, averaging only 22 +/- 26 ng/dl, in contrast to the consistent 52 +/- 15 ng/dl response in the follicular phase.
3 context sentences(design, population, supporting numbers)
Summary · context
Luteal phase responses differed from follicular phase responses in dex-pretreated women in the magnitude of the 17-hydroxyprogesterone response.
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290207
08HumanNot a test of Cosyntropin aloneNon-randomized trialActivity measurement
In dexamethasone-pretreated women, the cosyntropin response averaged 22 ± 26 ng/dl in the luteal phase versus 52 ± 15 in the follicular phase.
In plain wordsIn pretreated women, the hormone rise after cosyntropin was smaller and inconsistent in the luteal phase compared with the follicular phase.
Peptide
Cosyntropin
Outcome
Decrease17-hydroxyprogesterone increment
Study
n: not reported in source
Comparator
Follicular phase
Outcome group
Adrenal Function · Endocrine and hormones
Measurements
17-hydroxyprogesterone response
22 ng/dl
luteal phase
SD
26 ng/dl
luteal phase
17-hydroxyprogesterone response
52 ng/dl
follicular phase
SD
15 ng/dl
follicular phase
Source sentences
Summary
In the luteal phase, although the plasma 17-hydroxyprogesterone level at 30 min was higher, a response to ACTH was not consistently found, averaging only 22 +/- 26 ng/dl, in contrast to the consistent 52 +/- 15 ng/dl response in the follicular phase.
3 context sentences(design, population, supporting numbers)
Summary · context
Luteal phase responses differed from follicular phase responses in dex-pretreated women in the magnitude of the 17-hydroxyprogesterone response.
Summary · context
ACTH tests were performed with and without dexamethasone (dex) pretreatment to clarify the nature of the relationship between the absolute and incremental response (delta) to ACTH in normal men and women, hirsute women, adrenarchal children, and women heterozygous for congenital adrenal hyperplasia (CAH).
Summary · context
Cosyntropin was given as a 10 micrograms/m2 iv bolus dose at 0800-1000 h; dex (1 mg/m2) was given at 2200-2400 h the night before.
In this study, Cosyntropin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cosyntropin.
Report a problemFND-0298290208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.